AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will provide a corporate update at the upcoming BMO Capital Markets Prescription for Success Healthcare Conference in New York on Thursday, December 14 at 8:30 a.m. ET.
To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. The webcast and presentation will be archived for viewing for 60 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. Pegzilarginase (AEB1102), Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). An additional study of pegzilarginase combined with Merck’s pembrolizumab is expected to initiate in early 2018. Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of pegzilarginase for the treatment of patients with Arginase 1 Deficiency. The company is building a pipeline of additional product candidates targeting key amino acids.
For more information, please visit http://aegleabio.com.
Kelly Boothe, Ph.D.
Charles N. York II
Chief Financial Officer